Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Jun 19, 2026

Hims & Hers Stock Jumps After Barclays Raises Price Target

Hims & Hers Health Inc. (NYSE:HIMS) shares are climbing after Barclays reiterated its bullish stance and lifted its price target from $29 to $39. Here's what you need to know.

Benzinga • Jun 18, 2026

Hims & Hers: The Bull Case Remains Strong

Hims & Hers remains attractive at $33, supported by renewed Novo Nordisk partnership and unique access to patient demand. Despite weak Q1 2026 results—4% revenue growth, declining margins, and a net loss—international expansion and diversified categories are strengthening the long-term outlook. Management targets $6.5B+ revenue and $1.3B+ adjusted EBITDA by 2030, with valuation justified if retention and cross-sell improve.

Seeking Alpha • Jun 18, 2026

Living Longer Is Big Business. These Stocks Will Benefit.

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

Barrons • Jun 18, 2026

Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.89, moving +1.33% from the previous trading session.

Zacks Investment Research • Jun 17, 2026

Hims & Hers Enters A New Phase

The Novo Nordisk partnership transformed Hims & Hers Health, Inc. from a fringe obesity player into an official healthcare ecosystem participant. Short interest remains elevated near 30%-32% of the HIMS float, leaving roughly 63 million shares vulnerable to further covering. HIMS management targets at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030 through platform expansion.

Seeking Alpha • Jun 16, 2026

Hims & Hers Health Stock Slides Friday: What's Going On?

Hims & Hers Health Inc. (NYSE:HIMS) shares are trading lower on Friday as the stock digests last week's chief medical officer appointment and gives back some recent "repair rally" gains, even while market breadth stays constructive.

Benzinga • Jun 12, 2026

The GLP-1 stock nobody is pricing in isn't a drugmaker

Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults, are now on GLP-1s, and the drugs are reducing fast food's addressable market by an estimated 27-30%.

24/7 Wall Street • Jun 11, 2026

Hims & Hers Health (HIMS) Up 15.8% Since Last Earnings Report: Can It Continue?

Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 10, 2026

Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today

Hims & Hers Health, Inc. (HIMS) closed at $27.71 in the latest trading session, marking a -4.38% move from the prior day.

Zacks Investment Research • Jun 10, 2026